Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes
about
Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical ModelsCombined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.Analgesic efficacy, adverse effects, and safety of oxycodone administered as continuous intravenous infusion in patients after total hip arthroplasty.Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research.Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyPrescription drug abuse: insight into the epidemic.Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.Differences between opioids: pharmacological, experimental, clinical and economical perspectivesOpioid rotation in clinical practice.Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairmentMiconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4.Genetic risk signatures of opioid-induced respiratory depression following pediatric tonsillectomyMetabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry.In vitro metabolism of specific CYP2D and CYP3A opioid substrates using rat liver S9 fractions and mass spectrometry reveal a severe metabolic impairment with increasing age.Pharmacogenetics of opioids.Oral extended-release oxymorphone: a new choice for chronic pain relief.Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.Complicated pain management in a CYP450 2D6 poor metabolizer.Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.Parent and Metabolite Opioid Drug Concentrations in Unintentional Deaths Involving Opioid and Benzodiazepine CombinationsThe effect of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A-involving metabolism.Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.Pharmacogenomics of opioids and perioperative pain management.Combined oral prolonged-release oxycodone and naloxone in chronic pain management.Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications.The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients.Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs.Physiologically based pharmacokinetic modeling revealed minimal codeine intestinal metabolism in first-pass removal in rats.Codeine and opioid metabolism: implications and alternatives for pediatric pain management.Analgesic concentrations of oxycodone--a prospective clinical PK/PD study in patients with laparoscopic cholecystectomy.Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.Prescription Opioids. V. Metabolism and Excretion of Oxymorphone in Urine Following Controlled Single Dose Administration.Opioid rotation with extended-release opioids: where should we begin?Prescription opioids. III. Disposition of oxycodone in oral fluid and blood following controlled single-dose administration.Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model.
P2860
Q26764739-F1B65F50-91BA-4A9E-9295-E980625CE96BQ33520508-2ECE5245-8203-4483-BA25-5992B7867CD9Q33650528-DFF870EB-6F7E-45C6-9FA7-96A8A34E7B06Q33833207-DB6F0400-9C7A-44EA-884E-A3CF8ABCAE10Q34019354-A394B51E-19E8-4239-8448-9005FAC72C43Q34046633-931C5CC2-E56A-4394-96E2-74954660B0F3Q34123368-5449B3F1-2771-44C1-A005-E9223FC5B959Q34129781-A4D7A75E-B6DE-4F1D-9041-8F774CB45E2EQ34165511-FB382A2B-8E55-4C43-B193-86ECECD5E051Q34272502-13222928-54D0-4FF2-95D5-C7622C5E9633Q34305249-DEC65D8D-3632-492A-8F26-FF76F8E10763Q34608990-16B218D6-636A-4299-8A2D-E84991781F60Q34737242-6AC01D91-78A3-4528-91ED-941D28F5B3B2Q34872670-8CD1E492-0FB7-470B-8B47-80B7B6FE80B1Q35653564-7F296084-9602-4A38-A87C-11C85E88DFCBQ35913104-67028FC2-CAEB-4102-9CD4-268FD784ED19Q36070671-F73C0566-78EF-47F8-ABF7-CCC7792EF833Q36752672-51CEBD74-4FFC-40AB-B508-BE2D2B641FAEQ36895853-673F98C8-6A1B-4292-875A-0DCF3FA6BDCDQ36925745-3FBCF4F8-4A9B-4D89-A178-8C054C7363BDQ36994597-27AA45E3-5554-4ABD-8809-7FE275AA0F75Q37003866-4B3BF0FF-148E-41C4-A317-10F6D7AA7B42Q37094857-4D638FF9-617D-409C-9483-3D792F1755C1Q37523782-AC8767E6-F1CE-4E3B-B928-BD0109DFFB20Q37780212-648C7305-0674-42B9-989C-D7C6D6A55DC9Q38061498-B40D776F-417F-47B6-A650-8253DB3A24F7Q38065187-1FC00A0F-3301-427E-BDB2-2C017E327D18Q38100710-6CDA447B-6B5B-4032-9D04-DA0917A67B95Q38131859-C8F3C596-FC82-40A7-84C7-4708B45790D6Q38844220-18FD2F9A-5341-4F16-92F1-A5DEFE6150ABQ38851461-65DF81A6-FA31-4595-8429-771A7509668BQ38921093-ABBD5451-2308-4941-951F-3C8DBB3ADA88Q39124610-4B5703D7-97A2-4988-B52F-3AE91F10520FQ39190293-62C9A289-6701-48EC-ABCD-A9B5D2B6EFB3Q39255176-9921DA6C-573E-491C-AEA9-22FA14ED671FQ39298618-E10285D8-B963-4C37-8912-BACC2C3334E6Q39609516-8A650530-B739-4B87-9288-C8B78B4B8010Q40425662-E9AC78D4-6FA3-4C54-8A35-45F976E52CD1Q41581475-5CC4198F-2307-47BA-81B0-F74CF4FC022FQ41678423-617EC7AD-7AEA-418F-B786-2A3A6A207F0E
P2860
Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Quantitative contribution of C ...... iver and intestinal microsomes
@ast
Quantitative contribution of C ...... iver and intestinal microsomes
@en
Quantitative contribution of C ...... iver and intestinal microsomes
@en-gb
Quantitative contribution of C ...... iver and intestinal microsomes
@nl
type
label
Quantitative contribution of C ...... iver and intestinal microsomes
@ast
Quantitative contribution of C ...... iver and intestinal microsomes
@en
Quantitative contribution of C ...... iver and intestinal microsomes
@en-gb
Quantitative contribution of C ...... iver and intestinal microsomes
@nl
prefLabel
Quantitative contribution of C ...... iver and intestinal microsomes
@ast
Quantitative contribution of C ...... iver and intestinal microsomes
@en
Quantitative contribution of C ...... iver and intestinal microsomes
@en-gb
Quantitative contribution of C ...... iver and intestinal microsomes
@nl
P2093
P921
P356
P1476
Quantitative contribution of C ...... iver and intestinal microsomes
@en
P2093
Bojan Lalovic
Brian Phillips
Danny D Shen
Linda L Risler
William Howald
P304
P356
10.1124/DMD.32.4.447
P407
P577
2004-04-01T00:00:00Z